Levomil 20 Capsule ER contains Levomilnacipran 20 mg, an extended-release formulation indicated for the treatment of major depressive disorder (MDD) in adults. Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) that enhances neurotransmitter activity in the central nervous system by inhibiting the reuptake of serotonin and norepinephrine, thereby improving mood and alleviating depressive symptoms. The extended-release formulation allows for once-daily dosing, promoting better patient adherence and maintaining stable plasma drug concentrations. Clinical studies have demonstrated Levomilnacipran’s efficacy in reducing depressive symptoms, including mood disturbances, lack of energy, and cognitive impairment associated with MDD. Common adverse effects may include nausea, headache, hyperhidrosis, constipation, and increased heart rate, which are generally mild to moderate and tend to diminish with continued use. Caution is advised in patients with a history of cardiovascular disease, hypertension, or seizure disorders. Levomil 20 Capsule ER should be prescribed after careful assessment of the patient’s medical history and concomitant medications to avoid potential drug interactions. It is essential to monitor patients regularly for therapeutic response and any emergent side effects. Levomilnacipran should not be discontinued abruptly to prevent withdrawal symptoms; gradual dose tapering is recommended under medical supervision.